Unique Oral Drug Combo Acknowledged as Potential Hepatitis C Therapy
October 21, 2010
Combination of Two Oral Drugs Shows Promise for HCV in Small Study
By: Denise Napoli, Internal Medicine News Digital Network
A combination of two oral drugs for reducing viral load in hepatitis C patients had good safety and tolerability in a small, phase I study.
The finding, published online Oct. 15 in the Lancet, points the way toward an alternative to the current standard of care – subcutaneous pegylated interferon-alfa plus oral ribavirin – which has limited tolerability and efficacy.
The novel therapies that were tested in this study are RG7128, a nucleoside polymerase inhibitor, and danoprevir, a protease inhibitor, wrote Dr. Edward J. Gane of Auckland (New Zealand) Clinical Studies Ltd., an early-phase clinical pharmacology unit, and his colleagues.
Continue reading this entire article:
Chronic Hepatitis C Sufferers Might Benefit from Eurythmy
Nitazoxanide and IC41 Take on Interferon and Ribavirin